BeOne Medicines (ONC) AI Stock Analysis

• Market Cap: $32.14B
• Dividend Yield: N/A
• Average Volume (3M): 248.52K
• Price to Earnings (P/E): 115.5
• Beta (1Y): 0.87
• Revenue Growth: 49.80%
• EPS Growth: N/A
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 0.60
• Shares Outstanding: 109,720,300
• 10 Day Avg. Volume: 214,453
• 30 Day Avg. Volume: 248,521
• PEG Ratio: -0.18
• Price to Book (P/B): 7.60
• Price to Sales (P/S): 6.20
• P/FCF Ratio: 35.18
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 5.98
• Enterprise Value/Gross Profit: 6.84
• Enterprise Value/Ebitda: 42.74
• 1Y Price Target: $407.80
• Price Target Upside: 48.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): 6.11
• Revenue Forecast (FY): $6.40B

• Rating: 70 Outperform
• Price Target: $303.00 ▲(10.07% Upside)
• Action: Upgraded Date: 02/26/26
• Date: Action: Upgraded 02/26/26

The score is driven primarily by the 2025 profitability and free-cash-flow turnaround plus a strong earnings-call outlook (record product revenue and updated guidance). Technicals are supportive with an overall uptrend and neutral momentum. The biggest offset is valuation, with an extremely high P/E and no dividend yield provided.

Positive Factors

Profitability Turnaround

The 2025 inflection to positive operating profit and nearly $1B free cash flow indicates durable operational leverage and margin recovery. Sustained profitability improves internal funding for R&D and commercialization, supports reinvestment and debt reduction, and materially reduces reliance on external financing.

Strong Cash Position

A cash balance above $4B and significant quarterly free cash flow create a lasting liquidity buffer to fund late‑stage trials, launch activities, and opportunistic M&A without near‑term refinancing. This structural strength lowers execution risk and provides strategic optionality over multiple quarters.

Pipeline De‑risking

FDA breakthrough designation for Sonro materially raises the probability of accelerated development and prioritization, while multiple early‑stage proof‑of‑concept readouts signal productive R&D. These durable pipeline advances increase future product optionality and potential long‑term revenue streams.

Negative Factors

Historical Losses

A multi‑year history of losses and cash burn means the 2025 turnaround must be sustained to be credible. Prior volatility implies elevated execution risk: setbacks in launches, trial outcomes, or market uptake could quickly reverse margins and reintroduce funding pressure given the company’s recent recovery.

Clinical Timeline Risk

Delay of the MAMRO Phase III interim readout pushes potential approval and commercialization timelines, increases development costs, and defers revenue. Prolonged timelines compound capital intensity and raise the chance of changing competitive dynamics before potential market entry.

Competitive Pressure

Management’s decision to deprioritize a Phase III indication because of competition signals constrained addressable opportunity and margin risk. Structural competitive pressure can compress peak sales, force portfolio trade‑offs, and require higher commercial investment to defend share over the medium term.

BeOne Medicines Business Overview & Revenue Model

Company Description

BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.

How the Company Makes Money

BeOne Medicines primarily makes money by commercializing approved oncology drugs and recognizing revenue from the sale of those products to distributors, hospitals, pharmacies, and other healthcare channels (depending on the market). Additional revenue can come from collaboration arrangements (e.g., co-development and co-commercialization), licensing of intellectual property, and related milestone payments or royalties when partners commercialize products that incorporate BeOne’s assets, as well as potential contract manufacturing or supply arrangements tied to partnered products. Specific details on the company’s largest products, the exact mix of product vs. collaboration revenue, and named significant partnerships are not available in the provided prompt; therefore: null

BeOne Medicines Financial Statement Overview

Summary

2025 shows a clear inflection: revenue grew to $5.34B (+7.4% YoY) with a swing to positive operating profit ($447M), net income ($287M), and strong free cash flow ($942M). Balance sheet leverage looks moderate (debt ~$1.09B vs. equity ~$4.36B). The main constraint is the multi-year history (2020–2024) of sizable losses and cash burn, so durability of the turnaround remains the key risk.

Income Statement

The income statement shows a sharp profitability inflection in 2025, with revenue rising to $5.34B (+7.4% YoY) and a swing to positive operating profit ($447M) and net income ($287M) after multiple years of sizable losses (2020–2024). Revenue scaled rapidly from 2020–2024, but the company’s track record is still volatile given the depth and persistence of prior losses and negative profit margins in 2024 and earlier.

Balance Sheet

Leverage remains moderate and well-contained relative to equity: total debt was ~$1.09B vs. equity of ~$4.36B in 2025, following similarly conservative debt-to-equity levels in 2020–2024. Equity increased meaningfully from 2024 to 2025, supporting balance-sheet resilience. The main weakness is that returns on equity were negative in prior years (reflecting losses), so the balance sheet quality depends on sustaining the newly achieved profitability.

Cash Flow

Cash flow improved dramatically in 2025, with operating cash flow of $1.13B and free cash flow of $942M, versus negative operating and free cash flow in 2024 and earlier. This swing suggests improving underlying cash generation and operating discipline. However, the historical pattern includes several years of significant cash burn, so durability of free cash flow remains a key watch item.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.34B	3.81B	2.46B	1.42B	1.18B
Gross Profit	4.67B	3.22B	2.08B	1.13B	1.01B
EBITDA	616.77M	-396.44M	-1.12B	-1.72B	-1.39B
Net Income	286.93M	-644.79M	-881.71M	-2.00B	-1.46B
Balance Sheet
Total Assets	8.19B	5.92B	5.81B	6.38B	8.54B
Cash, Cash Equivalents and Short-Term Investments	4.55B	2.63B	3.17B	4.53B	6.62B
Total Debt	2.00B	1.08B	930.18M	596.67M	694.64M
Total Liabilities	3.83B	2.59B	2.27B	2.00B	2.40B
Stockholders Equity	4.36B	3.33B	3.54B	4.38B	6.13B
Cash Flow
Free Cash Flow	941.74M	-669.77M	-1.75B	-1.97B	-1.61B
Operating Cash Flow	1.13B	-140.63M	-1.16B	-1.50B	-1.30B
Investing Cash Flow	-276.15M	-548.35M	60.00M	1.08B	640.66M
Financing Cash Flow	1.06B	193.45M	416.48M	-18.97M	3.64B

BeOne Medicines Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 275.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ONC, the sentiment is Negative. The current price of 275.28 is below the 20-day moving average (MA) of 306.45, below the 50-day MA of 329.69, and below the 200-day MA of 314.04, indicating a bearish trend. The MACD of -15.64 indicates Positive momentum. The RSI at 28.55 is Positive, neither overbought nor oversold. The STOCH value of 5.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ONC.

BeOne Medicines Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ONC	70 Outperform	$32.14B	115.48	7.31%	―	49.80%	―
DGX	70 Neutral	$21.45B	19.42	13.88%	1.80%	13.74%	14.87%
BIIB	64 Neutral	$26.63B	19.96	7.28%	―	5.00%	-1.03%
TEVA	61 Neutral	$34.49B	25.43	20.09%	―	-0.25%	―
BNTX	57 Neutral	$22.44B	-17.95	-6.03%	―	7.04%	-25.24%
SMMT	54 Neutral	$12.03B	-14.92	-296.82%	―	―	-348.63%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%